The BalancedInvestor Club

CLNNW Market Analysis

Overview

Fundamentals

P/E ratio—
EPS (TTM)—0.0% YoY
Profit margin0.0%
Market cap$647.0MSmall cap

Valuation

Forward P/E
—
PEG ratio
—
P/B
—
P/S (TTM)
—
EV/EBITDA
—

Profitability & growth

ROE (TTM)
-1738.0%
Operating margin
-37653.0%
Revenue growth YoY
-82.8%
Dividend yield
—
Beta
0.79

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About Clene Inc

Clene Inc., a clinical-stage biopharmaceutical company, focuses on the development of various therapies for neurodegenerative diseases. The company is headquartered in Salt Lake City, Utah.

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
6550 SOUTH MILLROCK DRIVE, SALT LAKE CITY, UT
Fiscal year end
December
Latest quarter
Sep 30, 2025
Market cap$647.0M
Shares outstanding$0
52W high$0.04
52W low$0.00

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer